Tunicamycin potentiates drug cytotoxicity and vincristine retention in multidrug resistant cell lines

European Journal of Cancer Part A

Volumn 32, Issue 12, 1996, Pages 2164-2172

  Hiss, D ^a   Gabriels, G ^a   Jacobs, P ^b,c   Folb, P ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Wynberg Hospital   (South Africa)

Author keywords

anticancer drugs; cytotoxicity; glycoproteins; modulation of drug resistance; resistance modifiers; tunicamycin; vincristine transport

Indexed keywords

CISPLATIN; COLCHICINE; DOXORUBICIN; EPIRUBICIN; TUNICAMYCIN; VINCRISTINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TRANSPORT; HUMAN; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GLYCOPROTEINS; HUMANS; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED; TUNICAMYCIN; VINCRISTINE;

EID: 0030297682     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00262-6     Document Type: Article

References (61)

1. 1. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance, Hematol Oncol Clin North Am 1995, 9, 363-382.
2. 2. Ford JM. Modulators of multidrug resistance. Preclinical studies. Hematol Oncol Clin North Am 1995, 9, 337-361.
3. 3. Shustik C, Dalton W, Gros P. P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med 1995, 16, 1-78.
4. 4. Scarborough GA. Drug-stimulated ATPase activity of the human P-glycoprotein. J Bioenerg Biomembr 1995, 27, 37-41.
5. 5. Urbatsch IL, Senior AE. Effects of lipids on ATPase activity of purified Chinese hamster P-glycoprotein. Arch Biochem Biophys 1995, 316, 135-140.
6. 6. Lorico A, Rappa G, Srimatkandada S, et al. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene. Cancer Res 1995, 55, 4352-4360.
7. 7. Jandrig B, Wunderlich V. Membrane transport in multidrug resistance, development, and disease - AACR special conference in cancer research. J Cancer Res Clin Oncol 1992, 118, 238-239.
8. 8. Steinberg TH. Cellular transport of drugs. Clin Infect Dis 1994, 19, 916-921.
9. 9. Pereira E, Garnier-Suillerot A. Correlation between the short-term measurements of drug accumulation in living cells and the long-term growth inhibition. Biochem Pharmacol 1994, 47, 1851-1857.
10. 10. Fojo A, Akiyama S, Gottesman MM, Pastan I. Reduced drug accumulation in multiple drug-resistant human KB carcinoma cell lines. Cancer Res 1985, 45, 3002-3007.
11. 11. Nielsen D, Maare C, Skovsgaard T. Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil. Biochem Pharmacol 1995, 50, 443-450.
12. 12. Chu TM, Lin TH, Kawinski E. Detection of soluble P-glycoprotein in culture media and extracellular fluids. Biochem Biophys Res Commun 1994, 203, 506-512.
13. 13. Kast C, Canfield V, Levenson R, Gros P. Membrane topology of P-glycoprotein as determined by epitope insertion: transmembrane organization of the N-terminal domain of mdr3. Biochemistry 1995, 34, 4402-4411.
14. 14. Ichikawa M, Yoshimura A, Furukawa T, Sumizawa T, Nakazima Y, Akiyama S. Glycosylation of P-glycoprotein in a multidrug-resistant KB cell line, and in the human tissues. Biochim Biophys Acta 1991, 1073, 309-315.
15. 15. McDowell W, Schwarz RT. Dissecting glycoprotein biosynthesis by the use of specific inhibitors. Biochimie 1988, 70, 1535-1549.
16. 16. Sandvig K, Tonnessen TI, Olsnes S. Ability of inhibitors of glycosylation and protein synthesis to sensitize cells to abrin, ricin, Shigella toxin, and Pseudomonas toxin. Cancer Res 1986, 46, 6418-6422.
17. 17. Drori S, Eytan GD, Assaraf YG. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 1995, 228, 1020-1029.
18. 18. Elbein AD. Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains. Ann Rev Biochem 1987, 56, 497-534.
19. 19. Riehen N, Akiyama S, Shen DW, Gottesman MM, Pastan I. Multiple drug-resistant human KB carcinoma cells have decreased amounts of a 75-kDa glycoprotein. Proc Natl Acad Sci USA 1985, 82, 2330-2333.
20. 20. Richert ND, Aldwin L, Nitecki D, Gottesman MM, Pastan I. Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells. Biochemistry 1988, 27, 7607-7613.
21. 21. Shen D-W, Cardarelli C, Huang J, et al. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin or vinblastine show changes in expression of specific proteins. J Biol Chem 1986, 261, 7762-7770.
22. 22. Denizot F, Lang R. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Meth 1986, 89, 271-277.
23. 23. Tallarida RJ, Murray RB. Manual of Pharmacologic Calculations with Computer Programs. New York, Springer-Verlag, 1987, 137-139, 153-163.
24. 24. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt Biochem 1976, 72, 248-254.
25. 25. Brysk MM, Miller J, Chen SJ, Moller PC, Stach RW. Response of malignant and nonmalignant epidermal cell lines to tunicamycin. Cell Tissue Res 1986, 245, 215-221.
26. 26. Engstrom W, Larsson O. The effects of glycosylation inhibitors on the proliferation of a spontaneously transformed cell line (3T6) in vitro. J Cell Sci 1988, 90, 447-455.
27. 27. Larsson O, Engstrom W. The role of N-linked glycosylation in the regulation of activity of 3-hydroxy-3-methylglutarylcoenzyme A reductase and proliferation of SV40-transformed 3T3 cells. Biochem J 1989, 260, 597-600.
28. 28. Kabakoff BD, Doyle JW, Kandutsch AA. Relationships among dolichyl phosphate, glycoprotein synthesis, and cell culture growth. Arch Biochem Biophys 1990, 276, 382-389.
29. 29. Langan TJ, Slater MC. Isoprenoids and astroglial cell cycling: diminished mevalonate availability and inhibition of dolichol-linked glycoprotein synthesis arrest cycling through distinct mechanisms. J Cell Physiol 1991, 149, 284-292.
30. 30. Zhu X, Zeng Y, Lehrman MA. Evidence that the hamster tunicamycin resistance gene encodes UDP-GlcNAc:dolichol phosphate N-acetylglucosamine-1 -phosphate transferase. J Biol Chem 1992, 267, 8895-8902.
31. 31. Roninson IB. From amplification to function - the case of the MDR1 gene. Mutat Res 1992, 276, 151-161.
32. 32. Gervasoni JE, Taub RN, Rosado M, et al. Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells. Cancer Chemother Pharmacol 1991, 28, 93-101.
33. 33. Beck WT, Cirtain MC. Continued expression of Vinca alkaloid resistance by CCRF-CEM celts after treatment with tunicamycin or pronase. Cancer Res 1982, 42, 184-189.
34. 34. Ling V, Kartner N, Sudo T, Siminovitch L, Riordan JR. The multidrug resistance phenotype in Chinese hamster ovary cells. Cancer Treat Rep 1983, 67, 869-874.
35. 35. Chou TH, Kessel D. The effects of tunicamycin on anthracycline resistance in P388 murine leukemia cells. Biochem Pharmacol 1981, 30, 3134-3136.
36. 36. Greenberger LM, Croop JM, Horwitz SB, Arceci RJ, P-glycoproteins encoded by MDR1b in murine gravid uterus and multidrug-resistant tumor cell lines are differentially glycosylated. FEBS Lett 1989, 257, 419-421.
37. 37. Kramer R, Weber TK, Arceci R, et al Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. Br J Cancer 1995, 71, 670-675.
38. 38. Kessel D. Modes of resistance to antitumor agents. In Vivo 1994, 8, 829-834.
39. 39. Carlberg M, Hjertman M, Wejde J, Larsson O. Mevalonate is essential for growth activation of human fibroblasts: evidence for a critical role of protein glycosylation in the prereplicative period. Exp Cell Res 1994, 212, 359-366.
40. 40. Hunnicutt R, Keenan R. The preparation of tritiated tunicamycin. Analyt Biochem 1986, 159, 210-216.
41. 41. Ott RJ, Hui AC, Giacomini KM. Inhibition of N-linked glycosylation affects organic cation transport across the brush border membrane of opossum kidney (OK) cells. J Biol Chem 1992, 267, 133-139.
42. 42. Ichikawa M, Yoshimura A, Sumizawa T, et al. Interaction of organic chemicals with P-glycoprotein in the adrenal gland, kidney, and a multidrug-resistant KB cell. J Biol Chem 1991, 266, 903-908.
43. 43. Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R, Silvestrini R. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer 1994, 30A, 1002-1007.
44. 44. Bungo M, Fujiwara Y, Kasahara K, et al. Decreased accumulation as a mechanism of resistance to cis-diaminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res 1990, 50, 2549-2553.
45. 45. Chu G, Chang E. Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc Natl Acad Sci USA 1990, 87, 3324-3327.
46. 46. Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 1992, 31, 205-213.
47. 47. Zhen W, Link CJ, O'Connor PM, et al. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 1992, 12, 3689-3698.
48. 48. Chao CC, Huang YT, Ma CM, Chou WY, Lin-Chao S. Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line. Mol Pharmacol 1992, 41, 69-75.
49. 49. Misawa T, Kikkawa F, Oguchi H, et al. Accumulation of cis-diamminedichloroplatinum (II) and its analogues in sensitive and resistant human ovarian carcinoma cells. Oncology 1992, 49, 173-179.
50. 50. Kimiya K, Naito S, Soejima T, et al. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM. J Urol 1992, 148, 441-445.
51. 51. Futscher BW, Campbell K, Dalton WS. Collateral sensitivity to nitrosoureas in multidrug-resistant cells selected with verapamil. Cancer Res 1992, 52, 5013-5017.
52. 52. Morikage T, Bungo M, Inomata M, et al. Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line. Jpn J Cancer Res 1991, 82, 747-751.
53. 53. Kondo S, Yin D, Morimura T, Takeuchi J. Combination therapy with cisplatin and nifedipine inducing apoptosis in multidrug-resistant human glioblastoma cells. J Neurosurg 1995, 82, 469-474.
54. 54. Jamali MAA, Yin M, Mazzoni A, Bankkusli I, Rustum YM. Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933. Cancer Chemother Pharmacol 1989, 25, 77-83.
55. 55. Yang LY, Trujillo JM, Siciliano MJ, Kido Y, Siddik ZH, Su YZ. Distinct P-glycoprotein expression in 2 subclones simultaneously selected from a human colon carcinoma cell line by cis-diamminedichloroplatinum (II). Im J Cancer 1993, 53, 478-485.
56. 56. Mestdagh N, Pommery N, Saucier JM, et al. Chemoresistance to doxorubicin and cisplatin in a murine cell line. Analysis of P-glycoprotein, topoisomerase II activity, glutathione and related enzymes. Anticancer Res 1994, 14, 869-874.
57. 57. Chen G, Zeller J. Enhancement of cisplatin (DDP) antitumor activity by 3-aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivo. Cancer Chemother Pharmacol 1990, 26, 37-41.
58. 58. Utsugi T, Mattem MR, Mirabelli CK, Hanna K. Potentiation of topoisomerase II inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase II activity as a mechanism of potentiation. Cancer Res 1990, 50, 2636-2640.
59. 59. De Isabella P, Capranico G, Zunino F. The role of topoisomerase II in drug resistance. Life Sci 1991, 48, 2195-2205.
60. 60. Baguley BC, Holdaway KM, Fray LM. Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance. J Natl Cancer Inst 1990, 82, 398-402.
61. 61. Morrow CS, Cowan KH. Multidrug resistance associated with altered topoisomerase II activity - topoisomerases II as targets for rational drug design. J Natl Cancer Inst 1990, 82, 638-639.